Biomotion Sciences (SLXN) Stock

NASDAQ: SLXNHealthcare company in the biotechnology industry, based in Ramat Gan, USA.

Biomotion Sciences stock price chart

SLXN interactive chart →

SLXN stock quote & key statistics

Biomotion Sciences earnings per share

Income →
Earnings per share

Biomotion Sciences revenue & net income

Income →
RevenueNet income

Biomotion Sciences annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$11.9M—
FY2024$0-$16.4M-$5854.58
FY2023$0-$4.9M-$0.41
FY2022$0-$3.2M$0.42

Fiscal year ending December 31. Source: company filings via EODHD.

About Biomotion Sciences

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Biomotion Sciences stock FAQ

What is the Biomotion Sciences stock ticker symbol?

Biomotion Sciences trades on the NASDAQ under the ticker symbol SLXN.

What sector and industry is Biomotion Sciences in?

Biomotion Sciences is classified in the Healthcare sector, Biotechnology industry.

How many employees does Biomotion Sciences have?

Biomotion Sciences has about 13 full-time employees.

What were Biomotion Sciences's revenue and earnings last fiscal year?

Biomotion Sciences reported revenue of $0 and net income of -$11.9M in fiscal 2025.

When did Biomotion Sciences go public?

Biomotion Sciences stock began trading on August 16, 2024.

Biotechnology stocks

All Healthcare stocks →